Access count of this item: 90

Files in This Item:
File Description SizeFormat 
1061186X.2012.716848.pdf294.73 kBAdobe PDFView/Open
Title: Controlling the kinetics of interferon transgene expression for improved gene therapy.
Authors: Watcharanurak, Kanitta
Nishikawa, Makiya  kyouindb  KAKEN_id
Takahashi, Yuki  kyouindb  KAKEN_id
Takakura, Yoshinobu  kyouindb  KAKEN_id
Author's alias: 高橋, 有己
高倉, 喜信
Keywords: Non-viral vector
plasmid DNA
CpG motifs
plasmid backbone
Issue Date: Nov-2012
Publisher: Informa Healthcare
Journal title: Journal of drug targeting
Volume: 20
Issue: 9
Start page: 764
End page: 769
Abstract: Interferon (IFN) gene based therapy has been studied for the treatment of many diseases such as viral infections, cancer and allergic diseases. Non-viral vectors, like plasmid DNA, are promising ways for delivering IFN genes, because of their low immunogenicity and toxicity compared with viral vectors. Potent therapeutic effects of IFN gene transfer will depend on the level and duration of transgene expression after in vivo administration. Therefore, controlling the kinetics of transgene expression of IFNs is a rational approach for improved gene therapy. The design and optimization of plasmid vectors, as well as their route/method of administration, is the key to obtaining high and persistent transgene expression. In this review, we aim to present experimental evidence about the relationships among the properties of plasmid vectors expressing IFNs, the kinetics of transgene expression, and therapeutic effects as well as safety issues.
Rights: © 2012 Informa UK, Ltd.
This is not the published version. Please cite only the published version. この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。
DOI(Published Version): 10.3109/1061186X.2012.716848
PubMed ID: 22994266
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.